BRPI0720105A2 - Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos - Google Patents

Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos

Info

Publication number
BRPI0720105A2
BRPI0720105A2 BRPI0720105-2A2A BRPI0720105A BRPI0720105A2 BR PI0720105 A2 BRPI0720105 A2 BR PI0720105A2 BR PI0720105 A BRPI0720105 A BR PI0720105A BR PI0720105 A2 BRPI0720105 A2 BR PI0720105A2
Authority
BR
Brazil
Prior art keywords
amino acid
same
standard amino
amphtamine
manufacture
Prior art date
Application number
BRPI0720105-2A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Travis C Mickle
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of BRPI0720105A2 publication Critical patent/BRPI0720105A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
BRPI0720105-2A2A 2006-12-11 2007-12-10 Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos BRPI0720105A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86937506P 2006-12-11 2006-12-11
PCT/US2007/087028 WO2008073918A1 (en) 2006-12-11 2007-12-10 Non-standard amino acid conjugates of amphetamine and processes for making and using the same

Publications (1)

Publication Number Publication Date
BRPI0720105A2 true BRPI0720105A2 (pt) 2014-10-07

Family

ID=39512105

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720105-2A2A BRPI0720105A2 (pt) 2006-12-11 2007-12-10 Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos

Country Status (11)

Country Link
US (3) US7776917B2 (https=)
EP (1) EP2101571B1 (https=)
JP (1) JP2010512413A (https=)
CN (1) CN101594778A (https=)
AT (1) ATE509622T1 (https=)
AU (1) AU2007333105A1 (https=)
BR (1) BRPI0720105A2 (https=)
CA (1) CA2672138A1 (https=)
ES (1) ES2364865T3 (https=)
IL (1) IL198930A0 (https=)
WO (1) WO2008073918A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
CN102488652B (zh) 2006-03-16 2014-06-18 特瑞斯制药股份有限公司 含有药物-离子交换树脂复合物的经修饰释放的制剂
ES2364865T3 (es) * 2006-12-11 2011-09-15 Kempharm, Inc. Conjugados de ornitina de la anfetamina y procedimientos de fabricación y de utilización de los mismos.
EP2433655A3 (en) 2007-02-08 2013-05-15 Kempharm, Inc. Homoarginine-prodrugs of amphetamine
DE102007037478B3 (de) 2007-08-08 2008-04-30 Leifheit Ag Wäschetrockenständer
WO2010148305A1 (en) * 2009-06-19 2010-12-23 Cambrex Charles City, Inc. Methods and compositions for preparation of amphetamine conjugates and salts thereof
US20130059914A1 (en) 2010-04-21 2013-03-07 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
US8779191B2 (en) 2010-12-20 2014-07-15 Cambrex Charles City, Inc. Methods and compositions for preparing lisdexamfetamine and salts thereof
ES2883259T3 (es) * 2011-07-28 2021-12-07 Kempharm Inc Profármacos de metilfenidato, procesos para la obtención y uso de los mismos
WO2013019187A1 (en) * 2011-07-29 2013-02-07 Kempharm, Inc. Homoarginine prodrugs and/or conjugates of amphetamine and other stimulants and processes for making and using the same
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
WO2014002039A1 (en) * 2012-06-27 2014-01-03 Shire Ag Amphetamine prodrugs
EP2906208B1 (en) * 2012-10-09 2019-01-30 Sears, Douglas Therapeutic treatment
WO2016064914A1 (en) 2014-10-20 2016-04-28 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
JP2018534269A (ja) 2015-10-01 2018-11-22 エリージウム セラピューティクス， インコーポレイテッド 過剰摂取および乱用に抵抗性のポリサブユニットオピオイドプロドラッグ
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
MX389336B (es) 2016-11-15 2025-03-20 Klaria Pharma Holding Ab Formulacion farmaceutica.
CA3046486A1 (en) 2016-12-11 2018-06-14 Kempharm, Inc. Compositions comprising methylphenidate-prodrugs, processes of making and using the same
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
EP3595663A4 (en) 2017-03-17 2021-01-13 Elysium Therapeutics, Inc. MULTIPLE SUBUNITY OPIOID PRODRUGS WITH RESISTANCE TO OVERDOSE AND ABUSE
MA50120A (fr) * 2017-04-10 2020-03-11 Norman W Barton Méthodes de traitement à l'aide d'un promédicament d'amphétamine
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
AU2018351936A1 (en) * 2017-10-06 2020-05-14 Fundação Calouste Gulbenkian Treatment of obesity-related conditions
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2019199731A1 (en) * 2018-04-10 2019-10-17 Shire Pharmaceuticals Inc. Amphetamine prodrug and crystalline froms thereof
GB201808462D0 (en) * 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
US20220175699A1 (en) * 2019-03-06 2022-06-09 Ensysce Biosciences, Inc. Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
JP2023505687A (ja) 2019-12-11 2023-02-10 インスピルナ，インコーポレーテッド 癌の処置方法
US12599578B2 (en) 2021-03-09 2026-04-14 Ensysce Biosciences Inc. Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof
TW202309004A (zh) * 2021-08-24 2023-03-01 美商精神醫學公司 藉由使用受控和非受控中間體獲取ｍｄｍａ前驅藥之合成途徑
MX2024003466A (es) 2021-09-29 2024-06-04 Ensysce Biosciences Inc Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE539185A (https=) * 1954-06-28
US2881113A (en) * 1957-01-29 1959-04-07 Ortho Pharma Corp Therapeutically active compositions containing amphetamines
US2892753A (en) * 1957-02-26 1959-06-30 Boehringer Sohn Ingelheim Central nervous system stimulant
DE1493824A1 (de) 1964-01-27 1969-05-22 Hoffmann La Roche Verfahren zur Herstellung von Aminocarbonsaeureamiden
EP1041987B1 (en) * 1997-12-22 2006-04-19 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone
WO2001013921A1 (en) * 1999-08-23 2001-03-01 Ockert David M Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms
AU2001268353A1 (en) * 2000-06-09 2001-12-17 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
US6417184B1 (en) * 2000-09-19 2002-07-09 David M. Ockert Triple drug therapy for the treatment and prevention of acute or chronic pain
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
CA2477004C (en) * 2002-02-22 2011-05-10 Thomas Piccariello Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
WO2004091499A2 (en) * 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
MXPA05012850A (es) * 2003-05-29 2006-05-17 New River Pharmaceuticals Inc Compuestos de anfetamina resistentes al abuso.
WO2007033099A2 (en) 2005-09-13 2007-03-22 Shire Llc Prodrugs of phentermine
ES2364865T3 (es) * 2006-12-11 2011-09-15 Kempharm, Inc. Conjugados de ornitina de la anfetamina y procedimientos de fabricación y de utilización de los mismos.
EP2433655A3 (en) * 2007-02-08 2013-05-15 Kempharm, Inc. Homoarginine-prodrugs of amphetamine

Also Published As

Publication number Publication date
HK1131518A1 (en) 2010-01-29
ATE509622T1 (de) 2011-06-15
ES2364865T3 (es) 2011-09-15
EP2101571B1 (en) 2011-05-18
WO2008073918A1 (en) 2008-06-19
AU2007333105A1 (en) 2008-06-19
EP2101571A1 (en) 2009-09-23
CA2672138A1 (en) 2008-06-19
US20100292336A1 (en) 2010-11-18
US20080139653A1 (en) 2008-06-12
US8101661B2 (en) 2012-01-24
EP2101571A4 (en) 2010-01-13
US20090234018A1 (en) 2009-09-17
CN101594778A (zh) 2009-12-02
JP2010512413A (ja) 2010-04-22
US7776917B2 (en) 2010-08-17
IL198930A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
BRPI0720105A2 (pt) Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos
WO2008098151A3 (en) Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
BRPI0812877A2 (pt) " compostos de piperazina, uso de um composto de piperazina, composição, e, método para combater vegetação indesejada ".
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
PT2878307T (pt) Composição imunogénica.
BRPI0720972B8 (pt) compostos análogos de ciclopamina e composições farmacêuticas compreendendo os referidos compostos
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0607545A2 (pt) composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
CL2007002377A1 (es) Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
DOP2010000216A (es) (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina
TW200621313A (en) Pharmaceutical compositions
EA201000039A1 (ru) Фармацевтическая композиция, включающая солифенацин или его фармацевтически приемлемую соль
WO2007022956A3 (en) Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
WO2008051539A3 (en) Processes for preparing palonosetron salts
UY29857A1 (es) Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica.
BRPI0716250A2 (pt) Composto ou sal ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças, e, uso de um composto
ATE552832T1 (de) Antidepressivum-propharmaka
WO2006105482A3 (en) Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
BRPI0619018A2 (pt) composto ou um sal ou solvato farmaceuticamente aceitável do mesmo, uso de um composto, e, composição
NL1031705A1 (nl) Aminozuurderivaten.
WO2006078984A3 (en) Uses of methylphenidate derivatives
BRPI0816800A2 (pt) Composto, composição farmacêutica, e, uso de um composto.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: KEMPHARM, INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.